Breast Cancer

A subgroup analysis from a phase III study showed that certain patients may benefit more from eribulin than capecitabine, and quality of life data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

One in five African-American women with breast cancer carries an abnormality in at least one gene associated with breast cancer susceptibility.

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.

Biomarkers for sensitivity to etirinotecan pegol that are found in circulating tumor cells of breast cancer patients can be "reliably measured."

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer.

Patients with mutations of BRCA1 or BRCA2 who received tamoxifen after their initial diagnosis of breast cancer reduced their chances of developing contralateral or secondary breast cancer by more than half.

Exploratory analyses by intrinsic subtype showed that HER2-positive breast cancer is molecularly heterogeneous with varying degrees of sensitivity to HER2-targeted therapy.

Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center and Georgetown University Medical Center, discusses pregnant patients with breast cancer.

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses targeting HER2 in breast cancer.

Kathy S. Albain, MD, from the Loyola University Chicago and Cardinal Bernardin Cancer Center, discusses the difference between the 21-gene (Oncotype DX) assay and 70-gene (MammaPrint) assay in breast cancer.

Rebecca L. Aft, MD, PhD, from the Siteman Cancer Center, discusses the need to identify markers for patients with micrometastatic disease.

Adding the mTOR inhibitor everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer, and in the process, provided clues to the origin of trastuzumab resistance.

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, discusses the use of circulating tumor cells (CTCs) for prognosis and prediction in patients with breast cancer.

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses breast imaging across various cancer centers.

Combining paclitaxel with the investigational compound neratinib increased response rates versus neratinib alone in patients with HER2-positive metastatic breast cancer.

Elizabeth Mittendorf, MD, PhD, from MD Anderson Cancer Center, discusses the use of peptide vaccines for the treatment of breast cancer.

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the androgen receptor in breast cancer.

Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.

Women with breast cancer who are carriers of BRCA1 mutations have increased mortality compared with noncarriers, according to a retrospective study carried out in the Netherlands.

Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

Recently published clinical trial results support new radiation therapy protocols for many breast cancer survivors⎯protocols that could greatly improve collective outcome.

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, discusses the background and results of the S0221 trial in breast cancer.

Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.

Women with the highest expression of HER2 had the most benefit from T-DM1, while the presence of PIK3CA mutations had no effect on response to T-DM1 but did interfere with response to capecitabine/lapatinib.

Clifford A. Hudis, MD, chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, discusses the findings of the CALGB 40601 study in breast cancer.

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Joyce A. O'Shaughnessy, MD, from the Baylor Charles A. Sammons Cancer Center, reviews findings from Study 301, which compared eribulin mesylate to capecitabine for patients with locally advanced or metastatic breast cancer.

Rebecca L. Aft, MD, PhD, discusses the identification of patients with breast cancer at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.